Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,844 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.
Muscedere JG, Day A, Heyland DK. Muscedere JG, et al. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S120-5. doi: 10.1086/653060. Clin Infect Dis. 2010. PMID: 20597661 Review.
In a systematic review of applicable trials, VAP appears to have slight intensive care unit and low hospital-attributable mortality. ...Because of these findings, superiority trials of VAP treatment that use mortality as a primary end point are not possible. Equival …
In a systematic review of applicable trials, VAP appears to have slight intensive care unit and low hospital-attributable mortality. …
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI; National Cancer Institute of Canada Clinical Trials Group. Parulekar WR, et al. J Clin Oncol. 2005 Sep 1;23(25):6002-8. doi: 10.1200/JCO.2005.07.096. J Clin Oncol. 2005. PMID: 16135468
PATIENTS AND METHODS: We conducted a retrospective cohort study of a National Cancer Institute of Canada Clinical Trials Group phase III trial involving premenopausal patients randomized to receive cyclophosphamide, methotrexate, and fluorouracil (CMF), versus inten …
PATIENTS AND METHODS: We conducted a retrospective cohort study of a National Cancer Institute of Canada Clinical Trials Group …
Dissemination of the Canadian clinical practice guidelines for nutrition support: results of a cluster randomized controlled trial.
Jain MK, Heyland D, Dhaliwal R, Day AG, Drover J, Keefe L, Gelula M. Jain MK, et al. Crit Care Med. 2006 Sep;34(9):2362-9. doi: 10.1097/01.CCM.0000234044.91893.9C. Crit Care Med. 2006. PMID: 16850001 Clinical Trial.
DESIGN: A cluster-randomized trial with a cross-sectional outcome assessment at baseline and 12 months later. SETTING: Intensive care units in Canada. ...MEASUREMENTS AND MAIN RESULTS: The primary end point of this study was nutritional adequacy of enteral nutrition …
DESIGN: A cluster-randomized trial with a cross-sectional outcome assessment at baseline and 12 months later. SETTING: Intensi …
REducing Deaths due to OXidative Stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients.
Heyland DK, Dhaliwal R, Day AG, Muscedere J, Drover J, Suchner U, Cook D; Canadian Critical Care Trials Group. Heyland DK, et al. Proc Nutr Soc. 2006 Aug;65(3):250-63. doi: 10.1079/pns2006505. Proc Nutr Soc. 2006. PMID: 16923310 Review.
Supplementation with key nutrients, such as glutamine and antioxidants, is most likely to have a favourable effect on these physiological derangements, leading to an improvement in clinical outcomes. ...A novel design feature is the combined use of parenteral and en …
Supplementation with key nutrients, such as glutamine and antioxidants, is most likely to have a favourable effect on these physiolog …
Major bleeding in hemodialysis patients.
Holden RM, Harman GJ, Wang M, Holland D, Day AG. Holden RM, et al. Clin J Am Soc Nephrol. 2008 Jan;3(1):105-10. doi: 10.2215/CJN.01810407. Epub 2007 Nov 14. Clin J Am Soc Nephrol. 2008. PMID: 18003768 Free PMC article.
Time-dependent covariates and Cox proportional hazard models were used to determine the hazard rate of having a first major bleeding event. RESULTS: A total of 1028 person-years of exposure were observed from 255 patients with a median follow-up time of 3.6 y …
Time-dependent covariates and Cox proportional hazard models were used to determine the hazard rate of having a first major bleeding …
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.
Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Heyland DK, et al. Crit Care Med. 2008 Mar;36(3):737-44. doi: 10.1097/01.CCM.0B013E31816203D6. Crit Care Med. 2008. PMID: 18091545 Clinical Trial.
OBJECTIVE: To compare a strategy of combination therapy with a strategy of monotherapy with broad-spectrum antibiotics for suspected late ventilator-associated pneumonia. ...There was no difference in 28-day mortality between the combination and monotherapy g …
OBJECTIVE: To compare a strategy of combination therapy with a strategy of monotherapy with broad-spectrum antibiotics for sus …
Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes.
Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK; Canadian Critical Care Trials Group. Parker CM, et al. J Crit Care. 2008 Mar;23(1):18-26. doi: 10.1016/j.jcrc.2008.02.001. J Crit Care. 2008. PMID: 18359417 Clinical Trial.
MATERIALS AND METHODS: Data were collected as part of a large, multicentered trial of diagnostic and therapeutic strategies for patients (n = 739) with suspected VAP. ...The isolation of high risk pathogens from respiratory secretions was associated with higher 28-day
MATERIALS AND METHODS: Data were collected as part of a large, multicentered trial of diagnostic and therapeutic strategies for patie …
The value of pretest probability and modified clinical pulmonary infection score to diagnose ventilator-associated pneumonia.
Lauzier F, Ruest A, Cook D, Dodek P, Albert M, Shorr AF, Day A, Jiang X, Heyland D; Canadian Critical Care Trials Group. Lauzier F, et al. J Crit Care. 2008 Mar;23(1):50-7. doi: 10.1016/j.jcrc.2008.01.006. J Crit Care. 2008. PMID: 18359421 Clinical Trial.
Patients with high pretest probability had a lower PaO2/FiO2 ratio and a larger volume of secretions. High or moderate vs low pretest probability had high sensitivity (0.88; 95% confidence interval [CI], 0.87-0.89) and positive predictive value (0.87; 95% CI, 0.86-0 …
Patients with high pretest probability had a lower PaO2/FiO2 ratio and a larger volume of secretions. High or moderate vs low …
Previous cultures are not clinically useful for guiding empiric antibiotics in suspected ventilator-associated pneumonia: secondary analysis from a randomized trial.
Sanders KM, Adhikari NK, Friedrich JO, Day A, Jiang X, Heyland D; Canadian Critical Care Trials Group. Sanders KM, et al. J Crit Care. 2008 Mar;23(1):58-63. doi: 10.1016/j.jcrc.2008.01.009. J Crit Care. 2008. PMID: 18359422 Clinical Trial.
MATERIALS AND METHODS: We performed a retrospective analysis of a randomized controlled trial of different diagnostic and antibiotic strategies. In a subset of patients with pre-enrollment cultures, we examined agreement between cultures 1 to 3 days before su …
MATERIALS AND METHODS: We performed a retrospective analysis of a randomized controlled trial of different diagnostic and anti …
Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia. Secondary analysis of a multicenter randomized trial.
Albert M, Friedrich JO, Adhikari NK, Day AG, Verdant C, Heyland DK; Canadian Critical Care Trials Group. Albert M, et al. J Crit Care. 2008 Mar;23(1):74-81. doi: 10.1016/j.jcrc.2008.01.004. J Crit Care. 2008. PMID: 18359424 Clinical Trial.
The aim of the present study was to evaluate the relationship between EA or BAL Gram stains and final culture results in intensive care unit patients with a suspected VAP. ...RESULTS: Seven hundred forty patients were enrolled in the study; 35 did not have a Gram st …
The aim of the present study was to evaluate the relationship between EA or BAL Gram stains and final culture results in intensive care unit …
1,844 results
Jump to page
Feedback